FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945135792> ?p ?o ?g. }

• W2945135792 endingPage "108963" @default.
• W2945135792 startingPage "108963" @default.
• W2945135792 abstract "A . In response to doxorubicin-induced stress conditions, the cell responds by activating the adaptive defense system, thereby triggering the phosphorylation of GSK-3β at serine 9, resulting in an increase in the inhibition of GSK-3. The inhibited GSK-3 rescues Nrf2 from proteasomal degradation by suppressing the ubiquitination of Nrf2. The rescued Nrf2 is then translocated into the nucleus to activate the transcription of antioxidant genes, which prevents the generation of reactive oxygen species, leading to an increase in cell survival, a decrease in ovarian tissue damage and the maintenance of ovarian function. B . When the doxorubicin-induced toxicity is not reversed or is prolonged, the cellular adaptive defense mechanism against oxidative stress becomes decompensated by the exhaustion of the serine 9 phosphorylation of GSK-3β, resulting in a decrease in inactive GSK-3, followed by the ubiquitination and proteasomal degradation of Nrf2, a reduction in the Nrf2 that is translocated into the nucleus, a decrease in the transcription of antioxidant genes, an increase in the accumulation of reactive oxygen species, eventually leading to oxidative ovarian tissue damage and to a subsequent decrease in ovarian function • The inhibition of GSK-3 attenuates the DOX-induced increase in oxidative stress markers. • The inhibition of GSK-3 recovers low Nrf2 protein from DOX toxicity in the mouse ovary. • The inhibition of GSK-3 abrogates DOX toxicity on ovarian folliculogenesis. • The inhibition of GSK-3 protects the ovarian follicle pool against DOX-induced apoptosis. Chemotherapy induces ovarian failure in female children and young female cancer survivors. It has been shown that doxorubicin (DOX), an antitumor drug of the anthracycline group, causes gonadotoxicity via the stimulation of oxidative stress. The inhibition of glycogen synthase kinase-3 (GSK-3) was reported to be able to regulate oxidative stress. The present study assessed whether GSK-3 inhibition confers protection to the ovary against DOX-induced oxidative stress damage. An intraperitoneal injection of DOX was used to induce oxidative damage in the mouse ovary, while the inhibition of GSK-3 was achieved by the administration of SB216763, a small and potent GSK-3 inhibitor. DOX increased the mRNA expression levels of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the antioxidant genes heme-oxygenase-1 (HO-1) and catalase (CAT), while reducing the levels of glutathione peroxidase (GSH-Px) and superoxide dismutase-1 (SOD-1) compared with those of the control. When the GSK-3 inhibitor was combined with DOX increased more expression levels of Nrf2 mRNA and restored levels of GSH-Px and SOD-1 mRNA similar to those in the control group. DOX remarkably decreased the Nrf2 protein expression compared to that in the control, which was significantly associated with increased MDA levels. Interestingly, the SB216763 and DOX coadministration restored the Nrf2 protein expression and MDA levels to levels that were similar to those in the control. DOX significantly decreased the number of primordial, primary, preantral and antral follicles while increasing the number of atretic follicles compared to those in the control. SB216763 caused the drastic recovery of these follicles from the DOX effects. SB216763 and DOX coadministration significantly reduced the apoptotic index compared with that with DOX treatment. DOX decreased the serum AMH and E2 levels and increased the FSH levels compared to those in the controls. However, SB216763 and DOX coadministration restored AMH and E2 while decreasing the FSH levels compared to those in the DOX-treated group. In addition, SB216763 and DOX coadministration reduced the mature oocyte abnormalities that resulted from DOX-induced ovarian damage. Given these results, we suggest that GSK-3/Nrf2 is a promising protective pathway against doxorubicin-induced oxidative damage to the ovaries of females at reproductive ages. Thus, GSK-3 could be an attractive target for the research and development of new drugs for preserving ovarian function during chemotherapy." @default.
• W2945135792 created "2019-05-29" @default.
• W2945135792 creator A5016480737 @default.
• W2945135792 creator A5019010418 @default.
• W2945135792 creator A5037989560 @default.
• W2945135792 creator A5041844831 @default.
• W2945135792 creator A5048906828 @default.
• W2945135792 creator A5052697456 @default.
• W2945135792 creator A5057762106 @default.
• W2945135792 creator A5057991839 @default.
• W2945135792 date "2019-08-01" @default.
• W2945135792 modified "2023-10-01" @default.
• W2945135792 title "Protective properties of glycogen synthase kinase-3 inhibition against doxorubicin-induced oxidative damage to mouse ovarian reserve" @default.
• W2945135792 cites W1493104545 @default.
• W2945135792 cites W1512733937 @default.
• W2945135792 cites W1542790326 @default.
• W2945135792 cites W1964367654 @default.
• W2945135792 cites W1972343960 @default.
• W2945135792 cites W1973252291 @default.
• W2945135792 cites W1982608895 @default.
• W2945135792 cites W1982958012 @default.
• W2945135792 cites W1986631914 @default.
• W2945135792 cites W1993576370 @default.
• W2945135792 cites W1996989587 @default.
• W2945135792 cites W2009553345 @default.
• W2945135792 cites W2009815120 @default.
• W2945135792 cites W2011893748 @default.
• W2945135792 cites W2015531187 @default.
• W2945135792 cites W2020391016 @default.
• W2945135792 cites W2025907706 @default.
• W2945135792 cites W2026200928 @default.
• W2945135792 cites W2026873752 @default.
• W2945135792 cites W2028295337 @default.
• W2945135792 cites W2029742967 @default.
• W2945135792 cites W2034172400 @default.
• W2945135792 cites W2037291767 @default.
• W2945135792 cites W2051092344 @default.
• W2945135792 cites W2053265248 @default.
• W2945135792 cites W2054581336 @default.
• W2945135792 cites W2058138221 @default.
• W2945135792 cites W2068862545 @default.
• W2945135792 cites W2070469501 @default.
• W2945135792 cites W2075831840 @default.
• W2945135792 cites W2076013621 @default.
• W2945135792 cites W2079535840 @default.
• W2945135792 cites W2086082591 @default.
• W2945135792 cites W2100486472 @default.
• W2945135792 cites W2118318796 @default.
• W2945135792 cites W2122189144 @default.
• W2945135792 cites W2123122199 @default.
• W2945135792 cites W2128587010 @default.
• W2945135792 cites W2130239194 @default.
• W2945135792 cites W2135215861 @default.
• W2945135792 cites W2139608042 @default.
• W2945135792 cites W2140182328 @default.
• W2945135792 cites W2146472590 @default.
• W2945135792 cites W2149004752 @default.
• W2945135792 cites W2158380191 @default.
• W2945135792 cites W2165500341 @default.
• W2945135792 cites W2189840938 @default.
• W2945135792 cites W2234709467 @default.
• W2945135792 cites W2246363423 @default.
• W2945135792 cites W2260417559 @default.
• W2945135792 cites W2286917400 @default.
• W2945135792 cites W2319935270 @default.
• W2945135792 cites W2396888170 @default.
• W2945135792 cites W2490441649 @default.
• W2945135792 cites W2519315265 @default.
• W2945135792 cites W2522236431 @default.
• W2945135792 cites W2609519234 @default.
• W2945135792 cites W2625405719 @default.
• W2945135792 cites W2765805717 @default.
• W2945135792 cites W2766507915 @default.
• W2945135792 cites W2767263655 @default.
• W2945135792 cites W2777352963 @default.
• W2945135792 cites W2787551885 @default.
• W2945135792 cites W2796081133 @default.
• W2945135792 cites W2796106231 @default.
• W2945135792 cites W2802183709 @default.
• W2945135792 cites W2803303442 @default.
• W2945135792 cites W2804077203 @default.
• W2945135792 doi "https://doi.org/10.1016/j.biopha.2019.108963" @default.
• W2945135792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31125824" @default.
• W2945135792 hasPublicationYear "2019" @default.
• W2945135792 type Work @default.
• W2945135792 sameAs 2945135792 @default.
• W2945135792 citedByCount "19" @default.
• W2945135792 countsByYear W29451357922019 @default.
• W2945135792 countsByYear W29451357922020 @default.
• W2945135792 countsByYear W29451357922021 @default.
• W2945135792 countsByYear W29451357922022 @default.
• W2945135792 countsByYear W29451357922023 @default.
• W2945135792 crossrefType "journal-article" @default.
• W2945135792 hasAuthorship W2945135792A5016480737 @default.
• W2945135792 hasAuthorship W2945135792A5019010418 @default.
• W2945135792 hasAuthorship W2945135792A5037989560 @default.
• W2945135792 hasAuthorship W2945135792A5041844831 @default.
• W2945135792 hasAuthorship W2945135792A5048906828 @default.

• next